{
    "id": 9825,
    "fullName": "PTPN11 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PTPN11 mutant indicates an unspecified mutation in the PTPN11 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 5781,
        "geneSymbol": "PTPN11",
        "terms": [
            "PTPN11",
            "BPTP3",
            "CFC",
            "JMML",
            "METCDS",
            "NS1",
            "PTP-1D",
            "PTP2C",
            "SH-PTP2",
            "SH-PTP3",
            "SHP2"
        ]
    },
    "variant": "mutant",
    "createDate": "07/30/2015",
    "updateDate": "10/02/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3817,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In two clinical studies, PTPN11 mutations were frequently identified in patients with juvenile myelomonocytic leukemia and were found to be associated with poor survival (PMID: 19047918, PMID: 21901340), suggesting that this may serve as a future prognostic biomarker.",
            "molecularProfile": {
                "id": 9821,
                "profileName": "PTPN11 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50458,
                "name": "juvenile myelomonocytic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4191,
                    "pubMedId": 19047918,
                    "title": "Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19047918"
                },
                {
                    "id": 5428,
                    "pubMedId": 21901340,
                    "title": "Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21901340"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16071,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31467,
                "profileName": "IDH1 wild-type PTPN11 mut"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16070,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31467,
                "profileName": "IDH1 wild-type PTPN11 mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 9821,
            "profileName": "PTPN11 mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31467,
            "profileName": "IDH1 wild-type PTPN11 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}